CBAY Projected Dividend Yield
CymaBay Therapeutics Inc ( NASDAQ : CBAY )CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. 20 YEAR PERFORMANCE RESULTS |
CBAY Dividend History Detail CBAY Dividend News CBAY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |